INTERIM FORMULARY UPDATE

The following recommendations, made at the December 5, 2008 meeting of the Executive Formulary Committee, are approved:

Product(s) recommended to be added to the DADS/DSHS Drug Formulary based on the New Drug Applications:

<table>
<thead>
<tr>
<th>Generic Name</th>
<th>Brand Name</th>
<th>Dosage Form</th>
<th>Classification</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hepatitis A Inactivated &amp; Hepatitis B (Recombinant) Vaccine</td>
<td>Twinrix®</td>
<td>Injection: 720 EL.U. inactivated hepatitis A virus &amp; 20 mcg of hepatitis B surface antigen per ml</td>
<td>Immunological Agents</td>
</tr>
</tbody>
</table>

Other recommendation(s)/addition(s)/revisions(s) to the DADS/DSHS Drug Formulary:

Add the following Dosage Strengths to the Formulary:

- Dextromethorphan
  - Capsule: 15 mg
- Oxycodone
  - Tablet: 15 mg, 30 mg
- Prednisolone
  - Solution: 5 mg/5 ml
- Vitamin D
  - Capsule: 10,000 units
  - Tablet: 1,000 units

Recommendations based on Typical Antipsychotic Review:

Delete the following Dosage Strengths to the Formulary as they are not longer available:

- Chlorpromazine - Concentrate and Syrup
- Loxapine - Concentrate
- Mesoridazine – Injection, Liquid and Tablet
- Molindone – Concentrate
- Thioridazine - Concentrate

Approved:

[Signature]

Pharmacy Services Director
DSHS, Hospital Section